ArticleBiosafety and health2023
Epidemiology and characteristics of identified early mpox cases in Guangdong Province, China: Implications for prevention and control.
Article in Biosafety and health, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Development of monoclonal antibody-based methods for detecting mpox virus.Biosafety and health · 2026Article
- Clinical, epidemiological, and genomic evidence on mpox in mainland China, 2022-2025: a scoping review.Frontiers in microbiology · 2026Review
- Clinical epidemiology and viral genomics insights from a Chikungunya fever outbreak in South China, 2025.Frontiers in cellular and infection microbiology · 2026Article
- Global transmission characteristics of mpox outbreaks: a systematic review and meta-analysis.EClinicalMedicine · 2025Article
- Exploring the epidemiological characteristics of Mpox in the Arab Gulf countries.Scientific reports · 2025Article
- Clinical, Epidemiological, Virological Characteristics and Outcomes of 286 Patients Infected With Monkeypox Virus in China.Allergy · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In June 2023, the 2022 global mpox (monkeypox) outbreak began to affect Guangdong Province, one of the first regions in mainland China to report mpox cases. By July 10, 2023, 93 mpox cases had been reported in Guangdong Province. This study describes the epidemiological characteristics of these patients by collecting and analyzing data on demographics, sexual behavior, medical history, travel history, clinical symptoms, and diagnostic pathways and processes. The 93 mpox cases were all men aged 20-48 years, 95.70 % were men who have sex with men (MSM), and 48.39 % were HIV-positive. A few cases were married (to women) or living with children. The rash was present in almost all cases (98.91 %), with the most common sites being the genital and perianal areas (70.33 %). Intimate sexual contact was suspected to be the main route of infection, with a median incubation period of 8.5 days (IQR 5.0-11.8). The number of cases increased rapidly, and most patients had no history of international travel, suggesting sustained community transmission within the MSM population in Guangdong Province. In addition, 93.55 % of cases were detected by medical institutions, and more than half of these patients had two or more hospital visits before being diagnosed as an mpox case, indicating that clinicians need further training to increase their sensitivity to mpox. Targeted interventions should prioritize MSM while remaining vigilant for transmission to other populations, such as women and children.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.